Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

1.39
+0.03002.21%
Pre-market: 1.420.0300+2.16%08:15 EDT
Volume:1.89M
Turnover:2.62M
Market Cap:372.35M
PE:-66.88
High:1.42
Open:1.40
Low:1.36
Close:1.36
52wk High:4.08
52wk Low:1.14
Shares:267.88M
Float Shares:259.80M
Volume Ratio:0.56
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0208
EPS(LYR):-0.0208
ROE:-553.45%
ROA:5.44%
PB:11.42
PE(LYR):-66.88

Loading ...

Akebia Therapeutics Q3 Net Income USD 540 Thousand VS. Ibes Estimate USD -8.43 Million

THOMSON REUTERS
·
Nov 10, 2025

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Akebia Therapeutics Reports Vadadustat Reduces Death and Hospitalization in Dialysis Patients

Reuters
·
Nov 07, 2025

Akebia Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
Nov 04, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 04, 2025

Akebia Therapeutics (AKBA) Valuation in Focus After VALOR Trial Decision Alters Vafseo Strategy

Simply Wall St.
·
Oct 31, 2025

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Oct 30, 2025

Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics

TIPRANKS
·
Oct 30, 2025

Akebia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $6 From $8

THOMSON REUTERS
·
Oct 30, 2025

Akebia Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Oct 30, 2025

Akebia Therapeutics Drops Trial Plans for Anemia Treatment After FDA Meeting

Dow Jones
·
Oct 29, 2025

Akebia Therapeutics Halts VALOR Trial for Vadadustat

TIPRANKS
·
Oct 29, 2025

BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients

Reuters
·
Oct 29, 2025

Akebia Therapeutics Inc - Announces No Alignment With FDA on Valor Trial Design

THOMSON REUTERS
·
Oct 29, 2025

Akebia Therapeutics Inc - Will Not Initiate Valor Trial or Pursue Broad Label

THOMSON REUTERS
·
Oct 29, 2025

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

THOMSON REUTERS
·
Oct 29, 2025

Akebia Therapeutics Unveils New Vafseo Clinical Data at ASN Kidney Week 2025

Reuters
·
Oct 20, 2025

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook

Simply Wall St.
·
Oct 07, 2025